# US 2019/0314487 A1 · Multivalent influenza nanoparticle vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314487 A1
- Document ID: US20190314487A1
- Status: Published application
- Kind: A1
- Application number: 16/357,876
- Filed: 2019-03-19
- Published: 2019-10-17
- Earliest claimed: 2018-03-19
- Assignees: Novavax, Inc.
- Applicants: Novavax, Inc.
- Inventors: Sarathi BODDAPATI; Anushree HERWADKAR; Jason WONG; Yen-Huei LIN; Gale SMITH; Jing-Hui TIAN
- Web page: https://patentgrep.com/patent/US20190314487A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16171: Demonstrated in vivo effect
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16271: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

## Claims

### Claim 1

A multivalent immunogenic influenza composition comprising
(a) a detergent-core nanoparticle, wherein the detergent-core nanoparticle comprises a recombinant influenza hemagglutinin (HA) glycoprotein from a Type B influenza strain; and
(b) a Hemagglutinin Saponin Matrix Nanoparticle (HaSMaN), wherein the HaSMaN comprises a recombinant influenza HA glycoprotein from a Type A influenza strain and ISCOM matrix adjuvant; and
(c) a pharmaceutically acceptable buffer.

### Claim 2 (depends on 1)

The composition of claim 1 further comprising one or more detergent-core nanoparticles and/or one or more HaSMaNs.

### Claim 3 (depends on 1)

The composition of claim 1 wherein each of the nanoparticles is a trypsin-resistant nanoparticle.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the ISCOM matrix adjuvant is Matrix M.

### Claim 5 (depends on 6)

The composition of claim 6, wherein the Matrix M contains Fraction A Matrix and Fraction C Matrix (85:15; w/w).

### Claim 6 (depends on 1)

The composition of claim 1 wherein the detergent is PS-80.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the PS-80 detergent is present at about 0.03% to about 0.5%.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the PS-80 detergent is present at about 0.04%.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the influenza strain is of a subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the pharmaceutically acceptable buffer comprises (i) sodium phosphate at about 25 mM; (ii) sodium chloride at about 150 mM; (iii) arginine hydrochloride at about 100 mM; (iv) trehalose at about 5%; wherein the composition pH is at about 7.5.

### Claim 11 (depends on 1)

A prefilled syringe or blow-fill seal container comprising the composition of claim 1.

### Claim 12 (depends on 10)

The prefilled syringe or blow-fill seal container of claim 10, wherein the composition is stable for at least 12 months.

### Claim 13 (depends on 11)

The prefilled syringe or blow-fill seal container of claim 11, wherein the composition is stable at 25° C.

### Claim 14 (depends on 1)

A method of stimulating an immune response against influenza comprising administering the multivalent influenza composition of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition is administered intramuscularly.

### Claim 16

A HaSMaN (Hemagglutinin Saponin Matrix Nanoparticle) comprising an ISCOM matrix particle and recombinant influenza HA glycoprotein trimers, wherein the HA glycoprotein is from a Type A influenza strain, wherein the HA glycoprotein tail is associated with the particle and wherein the HA glycoprotein head extends distally from the particle.

### Claim 17 (depends on 16)

The HaSMaN of claim 16, wherein the Type A influenza strain is of a subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.

### Claim 18 (depends on 16)

A composition comprising, the HaSMaN of claim 16, and a pharmaceutically acceptable buffer or carrier.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the adjuvant is present at about 50 μg to about 75 μg per dose.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the recombinant influenza HA glycoprotein from the Type B influenza strain and the recombinant influenza HA glycoprotein from the Type A influenza strain are both present in an amount of about 60 μg.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the recombinant influenza HA glycoprotein from the Type B influenza strain and the recombinant influenza HA glycoprotein from the Type A influenza strain are both wild type influenza HA glycoproteins.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the recombinant influenza HA glycoprotein from the Type B influenza strain and the recombinant influenza HA glycoprotein from the Type A influenza strain are expressed in a host cell.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the host cell is an insect Sf9 cell.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the recombinant influenza HA glycoprotein from the Type B influenza strain and the recombinant influenza HA glycoprotein from the Type A influenza strain are expressed using a baculovirus.

### Claim 25

A method of preparing a HaSMaN comprising combining a detergent core nanoparticle with a saponin-based matrix adjuvant.

### Claim 26 (depends on 25)

The method of claim 25, wherein the saponin-based matrix adjuvant is an ISCOM matrix adjuvant.

### Claim 27 (depends on 26)

The method of claim 26, wherein the ISCOM Matrix adjuvant is Matrix M.

### Claim 28 (depends on 27)

The method of claim 27, wherein the Matrix M contains Fraction A Matrix and Fraction C Matrix (85:15; w/w).

### Claim 29 (depends on 25)

The method of claim 25, wherein the detergent is PS-80.

### Claim 30 (depends on 25)

The method of claim 25, comprising incubating the detergent core nanoparticle with the saponin-based matrix adjuvant for at least about 4 hours.

### Claim 31 (depends on 30)

The method of claim 30, comprising incubating the detergent core nanoparticle with the saponin-based matrix adjuvant at a temperature of about 25° C. for at least about 24 hours.

### Claim 32 (depends on 25)

The method of claim 25, wherein the detergent-core nanoparticle comprises a recombinant influenza hemagglutinin (HA) glycoprotein from a Type A influenza strain.

### Claim 33 (depends on 32)

The method of claim 32, wherein the Type A influenza strain is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.
